Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Advances study observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which